Celltrion to highlight Remsima SC clinical data at UEG Week 2026

What happened: Celltrion will present clinical data on Remsima SC and promote its IBD portfolio at UEG Week 2026 in Barcelona, Spain, from Saturday to Tuesday. Key numbers: Remsima IV and SC held a combined 71 percent market share in Europe; Yuflyma accounted for 24 percent, per first-quarter IQVIA data cited by the company. Last year's UEG Week drew more than 12,100 participants from 115 countries. Why it matters: Celltrion aims to build on its position in Europe's IBD treatment market and use its European direct-sales network to expand sales across the portfolio.

Celltrion will present clinical data on Remsima SC and promote its IBD portfolio at UEG Week 2026 in Barcelona, Spain, from Saturday to Tuesday.

Celltrion aims to build on its position in Europe's IBD treatment market and use its European direct-sales network to expand sales across the portfolio.